Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 214

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 214
---
 bonuses, and benefits for these positions. Reimbursable salaries paid to RBx pursuant to this agreement are $125,000 per month. Reimbursable salaries paid to RBx were $375,000 and $1,050,000 during the three and nine months ended September 30, 2024 (2023 - $nil and $nil). Additional expenses of $36,829 and $161,006 were incurred by RBx on behalf of the Company in the three and nine months ended September 30, 2024. The Company paid $403,506 and $1,233,534 to RBx during the three and nine months ended September 30, 2024 (2023 - $nil and $nil). The total amount of accounts payable to RBx was $143,422 as of September 30, 2024 (December 31, 2023 - $165,950).

In connection with the convertible notes issued by the Company on May 3, 2024 (Note 4), related parties consisting of key management personnel subscribed for 168,750 convertible notes in the principal amount of $675,000. Upon conversion the Company settled the convertible notes, along with accrued but unpaid interest, with 172,953 common shares.

<div align='center'>F-17</div>

Key management personnel compensation during the periods ended September 30, 2024 and 2023 comprised:

|                       |     |    2024 |     | For the three months 
 ended September 30,  
 2023                 |     |      2024 |     | For the nine months 
 ended September 30, 
 2023                |
|:----------------------|:----|--------:|:----|:---------------------|:----|----------:|:----|:--------------------|
|                       |     |       $ |     | $                    |     |         $ |     | $                   |
| Salaries and benefits |     | 359,489 |     | -                    |     | 1,014,849 |     | -                   |
| Share-based payments  |     |       - |     | -                    |     |   435,717 |     | -                   |
| Total                 |     | 359,489 |     | -                    |     | 1,450,566 |     | -                   |

12. Capital management

The Company's capital management objectives are to maintain financial flexibility in order to pursue its strategy